Resonance Specialties Limited (RESONANCE) Fair Value & Analysis
Basic Materials · IN · Market cap ₹1.6B
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price +6.0% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹77.93 – ₹146.60 · fair‑value band ₹116.68 – ₹195.55 · the ₹136.25 price screens below the ₹156.12 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Resonance Specialties Limited (RESONANCE) currently trades at ₹136.25, while our model-based Fair Value estimate is ₹156.12 — implying the stock looks roughly 14.6% undervalued today. We read business quality at 71/100 (solid quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Resonance Specialties Limited generated revenue of ₹902M at a net margin of 11.5%. Revenue grew 1.1% year over year. It earns a return on equity of 15.2%. Net debt stands at ₹18.8M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹116.68 (bear case) to ₹195.55 (bull case); at ₹136.25, the current price sits within that range. The share trades about 8% below its 52-week high and 77% above its 52-week low, currently above its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -43% fair-value upside — at 15%, RESONANCE screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Resonance Specialties Limited engages in the manufacture and marketing of specialty chemicals in India and internationally. It offers pyridine, a chemical used in manufacturing agrochemicals, pharmaceuticals and bulk drugs, dyes, rubber chemicals, etc.; cyanopyridines that are applied in manufacturing of niacinamide; and picolines, including alpha, beta, and gamma picolines used in manufacturing vinyl latex rubber, vitamin B3, and anti-tuberculosis drugs. The company also provides nutritional drug products, such as zinc and chromium picolinate, chromium polynicotinate, niacin, niacinamide, and Isoniazid; alpha picolinic and dipicolinic acids; solvents, including acetonitrile and valeronitrile; lutidines for anti-ulcer drugs; and collidines for omeprazole, lansoprazole, rebaprazole, and esomeprazole. The company was formerly known as Armour Polymers Limited. Resonance Specialties Limited was incorporated in 1989 and is based in Mumbai, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Resonance Specialties Limited reported revenue of ₹902M in FY2025 versus ₹742M in FY2021, a compound +5.0%/yr. Reported net income was ₹104M in FY2025, compounding −4.2%/yr from FY2021.
Is RESONANCE fairly valued? → Check now
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Linde plc LIN | €425.60 | €106.89 | -75% |
| Shin-Etsu Chemical Co SHECY | $22.62 | $12.94 | -43% |
| BASF SE BASFY | $14.21 | $7.95 | -44% |
| Ningxia Baofeng Energy Group 600989 | ¥21.72 | ¥42.42 | +95% |
| Dow Inc D1OW34 | R$43.91 | R$31.57 | -28% |
| Ganfeng Lithium Group 002460 | ¥67.60 | ¥22.08 | -67% |
| Hengli Petrochemical Co 600346 | ¥16.96 | ¥15.04 | -11% |
| Zangge Mining Company 000408 | ¥78.96 | ¥50.88 | -36% |
| Rongsheng Petrochemical Co 002493 | ¥11.15 | ¥3.01 | -73% |
| Zhejiang Juhua Co 600160 | ¥40.39 | ¥19.73 | -51% |
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Resonance Specialties Limited (RESONANCE) undervalued?
What is the fair value of RESONANCE?
What is the quality score of RESONANCE?
What is the revenue of Resonance Specialties Limited (RESONANCE)?
What is the net profit margin of RESONANCE?
Does Resonance Specialties Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.